MG
ORIC icon

Michael Gelband’s Oric Pharmaceuticals ORIC Stock Holding History

Michael Gelband’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-186,145
Closed -$2.36M – 1933
2026
Q1 		$2.36M Buy
186,145
+77,310
+71% +$878K 0.02% 725
2025
Q4 		$890K Buy
+108,835
New +$1.25M 0.01% 1036
2025
Q1 		– Sell
-23,417
Closed -$189K – 1853
2024
Q4 		$189K Buy
+23,417
New +$215K ﹤0.01% 1369

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's ORIC Position: Q2 2026 in Review

Michael Gelband sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 186,145 shares — an estimated $2.36M sold.

Michael Gelband first reported a position in ORIC in Q4 2024 and held it in 3 quarters. The position peaked at $2.36M in Q1 2026. 179 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Michael Gelband reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 186,145 Oric Pharmaceuticals shares in Q2 2026, an estimated $2.36M.
  • Michael Gelband first reported a position in Oric Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Michael Gelband's Oric Pharmaceuticals position peaked at $2.36M in Q1 2026.
  • 179 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.